FAST NEWS: Junshi Biosciences announces A-Share buyback
The latest: Drug developer Shanghai Junshi Biosciences Co. Ltd. (1877.HK; 688180.SH) said on Sunday its board has approved a plan to buy back some of its A-shares for up to 58 yuan per…
FAST NEWS: Everest Medicines Plunges After Terminating Breast Cancer Drug Deal
The latest: Everest Medicines Ltd. (1952.HK) announced Tuesday that it is terminating its agreement to develop Gilead Science’s (GILD.US) Sacituzumab Govitecan breast cancer drug for the China market. Looking up:…
Recent Articles
RELATED ARTICLES
-
Will Junshi Bio’s loss-making headaches ease with landmark U.S. drug approval?
1877.HK 688180.SHG -
Junshi hopes new scientist CEO can cure its woes
1877.HK 688180.SHG
-
BeiGene still bleeding red ink despite blockbuster drug
BGNE.US 6160.HK 688235.SHG
